Corcept Therapeutics Inc. reported first‑quarter 2026 results, posting a net loss of $0.30 per share and revenue of $164.9 million, down from $157.2 million in the same quarter a year earlier. The loss reflects a $31.8 million net loss versus a $20.5 million net income in Q1 2025.
Revenue fell short of consensus estimates, which ranged from $172.4 million to $196.4 million, a miss of between $7.5 million and $31.5 million. The shortfall was driven by lower‑than‑expected sales in the endocrinology segment and operational disruptions linked to a specialty pharmacy vendor transition, rather than a one‑time restructuring charge.
Operating expenses rose sharply as the company accelerated the launch of Lifyorli and expanded growth initiatives in its Cushing’s syndrome business. The increased spend, combined with the higher cost of the oncology launch, pushed the operating margin to –30.1 % from 2.2 % a year earlier and contributed to the net loss.
Despite the quarterly miss, management raised its full‑year revenue outlook to $950 million–$1.05 billion, up from the prior guidance of $900 million–$1.00 billion. The upgrade reflects record patient starts for Korlym, strong early uptake of Lifyorli, and confidence that the oncology platform will drive accelerated growth in the coming quarters.
Investors weighed the revenue miss and net loss against the optimistic outlook. The market reaction was mixed, with analysts noting the company’s ability to generate record patient starts while also highlighting the short‑term impact of higher operating costs.
"Our revenue in the first quarter of 2026 was $164.9 million compared to $157.2 million in the prior year period. We have increased our 2026 revenue guidance to $950 million–$1.05 billion. Net loss was $31.8 million in the first quarter of 2026 compared to net income of $20.5 million in the first quarter of last year. Our cash and investments on March thirty‑first were $515 million." – Atabak Mokari, CFO & Treasurer
"March and April marked all‑time highs in the number of patients starting treatment. We have increased our 2026 revenue guidance to $950 million–$1.05 billion." – Joseph K. Belanoff, M.D., CEO
"The FDA’s approval of Lifyorli in platinum‑resistant ovarian cancer is welcome news for women with this difficult‑to‑treat disease. It also underscores the potential of our oncology program, which we believe will produce medications to treat many tumor types and a broad array of combination therapies." – Joseph K. Belanoff, M.D., CEO
"36 days into our launch, things are going very well… Prescriptions have already been written by over 200 physicians… Lifyorli’s inclusion in the National Comprehensive Cancer Network… guidelines as a preferred regimen just 15 days after approval will support strong adoption and payer access." – Roberto Vieira, President of Oncology
"Our endocrine business represents the bulk of our guidance range just given where we are with oncology." – Atabak Mokari, CFO & Treasurer
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.